Profile data is unavailable for this security.
About the company
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.
- Revenue in USD (TTM)0.00
- Net income in USD-28.37m
- Incorporated2013
- Employees22.00
- LocationHepion Pharmaceuticals Inc399 Thornall StEDISON 08837-2236United StatesUSA
- Phone+1 (732) 902-4000
- Fax+1 (732) 902-4100
- Websitehttps://hepionpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzolytics Inc | 0.00 | -119.19k | 3.66m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.03m | 3.71m | 3.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | 0.9986 | 0.00 | -- | -- | 0.00 | -139.98 | -104.18 | -163.33 | -111.05 | -- | -- | -- | -- | -- | -563.88 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 3.72m | 0.00 | -- | 0.4104 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.85m | -35.97m | 3.82m | 27.00 | -- | 0.2424 | -- | 2.07 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 3.84m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 3.87m | 22.00 | -- | 2.08 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 3.88m | 5.00 | -- | 1.79 | -- | 7.65 | -4.95 | -4.95 | 0.5919 | 1.79 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Correlate Energy Corp | 5.65m | -34.51m | 3.89m | 19.00 | -- | -- | -- | 0.6888 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.33 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Therapeutic Solutions International Inc | 91.38k | -2.00m | 3.91m | 3.00 | -- | 2.84 | -- | 42.76 | -0.0005 | -0.0005 | 0.00002 | 0.0003 | 0.0252 | 1.29 | 5.24 | 30,460.00 | -63.67 | -162.32 | -153.29 | -- | 65.18 | 67.79 | -2,530.31 | -2,391.85 | 0.3883 | -6.94 | 0.3164 | -- | -52.13 | 95.35 | 43.11 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -15.90m | 3.91m | 9.00 | -- | 1.50 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.20m | 3.91m | 8.00 | -- | 3.07 | -- | -- | -10.29 | -10.29 | 0.00 | 0.3805 | 0.00 | -- | -- | 0.00 | -123.53 | -- | -147.27 | -- | -- | -- | -- | -- | -- | -4.32 | 0.5076 | -- | -- | -- | -112.71 | -- | -- | -- |
| TNF Pharmaceuticals Inc | 0.00 | -7.07m | 3.91m | 9.00 | -- | 0.1449 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 3.92m | 4.00 | -- | 3.47 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
| Azitra Inc | 408.20k | -9.96m | 3.98m | 10.00 | -- | 0.2904 | -- | 9.75 | -12.12 | -12.12 | 0.1151 | 1.80 | 0.0595 | -- | 1.83 | 40,820.00 | -145.30 | -- | -194.72 | -- | -- | -- | -2,440.46 | -- | -- | -- | 0.0191 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.99m | 5.00 | -- | 0.547 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Hepion Pharmaceuticals Inc's reporting currency: US Dollar USD
14.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 516.00k | 8.90% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 126.31k | 2.18% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 82.95k | 1.43% |
| Geode Capital Management LLCas of 30 Jun 2024 | 44.54k | 0.77% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 15.68k | 0.27% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 14.64k | 0.25% |
| RBC Capital Markets LLC (Investment Management)as of 30 Jun 2024 | 14.50k | 0.25% |
| XTX Markets LLCas of 30 Jun 2024 | 10.16k | 0.18% |
| PNC Bank, NA (Investment Management)as of 30 Sep 2024 | 7.72k | 0.13% |
| Tower Research Capital LLCas of 30 Jun 2024 | 5.81k | 0.10% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
